MWNA
OMED

Marshall Wace North America’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Marshall Wace North America’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-187,088
Closed -$561K – 1722
2017
Q2 		$561K Buy
+187,088
New +$776K ﹤0.01% 1069
2013
Q4 		– Sell
-64,649
Closed -$990K – 958
2013
Q3 		$990K Buy
+64,649
New +$1.2M 0.03% 346

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Marshall Wace North America's OMED Position: Q3 2017 in Review

Marshall Wace North America sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2017, closing a stake of 187,088 shares — an estimated $561K sold.

Marshall Wace North America first reported a position in OMED in Q3 2013 and held it in 2 quarters. The position peaked at $990K in Q3 2013. 58 funds tracked by Wall St. Rank hold OMED as of Q3 2017.

  • Marshall Wace North America reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Marshall Wace North America sold 187,088 OncoMed Pharmaceuticals, Inc. shares in Q3 2017, an estimated $561K.
  • Marshall Wace North America first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 2 quarters.
  • Marshall Wace North America's OncoMed Pharmaceuticals, Inc. position peaked at $990K in Q3 2013.
  • 58 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2017.

Based on Marshall Wace North America's 13F filing for Q3 2017, filed 13 Nov 2017.